Genetics Institute deal

The companies will share development costs and GENIZ will receive milestones. In 1994, reimbursement for rhIL-12 R&D expenses and initial milestone payments to the Cambridge, Mass., company will exceed $20 million. GENIZ will supply rhIL-12 to the joint venture and will receive royalties. The company retains marketing rights in North America, while Wyeth-Ayerst International retains marketing rights outside of North America and Japan. ...